Author :
V V Mishra, Sumesh Chaudhary, Khushali Gandhi, Urmila Sharma, Ushma Patel
Volume :
2
Issue :
2
Abstract :
Background and objectives: Iron deficiency is common among women of childbearing age in both the developed and developing countries. Intravenous Ferric carboxy maltose (FCM) is a novel molecule which can be safely administered in a single dose as large as 1000mg in as little as 15 minutes with no significant adverse effects.
Methods: A hospital based prospective study included 39 antenatal women >20-36 weeks gestation and 119 postpartum women with documented iron deficiency anemia. Intravenous Ferric carboxy maltose (FCM) was administered and improvement in hemoglobin and iron stores was assessed after 3 weeks. Safety of intravenous FCM was also assessed during the study.
Results: There was a significant improvement in hemoglobin over a period of 3 weeks from mean Hb 8.97±1.05 gm/dL to 11.34±0.90 gm/dL with p value